[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470079":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":55,"collaborators":18,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":18,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":35,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Chongqing University Cancer Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","EXPERIMENTAL","transfusion of autologous blood containing haematopoietic stem cells after conventional chemotherapy",[13],"Other: Autologous blood transfusion with haematopoietic stem cells",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","enrolled ovarian cancer patients receive conventional chemotherapy",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Autologous blood transfusion with haematopoietic stem cells","Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 \u002F L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109\u002FL, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109\u002FL.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.",[9],[25],{"name":26,"affiliation":5,"role":27},"Dongling Zou, M.D.","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","13657690699","cqzl_zdl@163.com",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Chongqing","Chongqing Municipality","400030","China","CN",{"type":42,"coordinates":43},"Point",[44,45],106.55771,29.56026,{"lat":45,"lon":44},[48,49,50,52],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},{"name":26,"role":27,"phone":18,"phoneExt":18,"email":18},{"name":51,"role":27,"phone":18,"phoneExt":18,"email":18},"Yao Liu, M.D.",{"name":53,"role":54,"phone":18,"phoneExt":18,"email":18},"Na Zhang, M.M.","SUB_INVESTIGATOR",{"type":56,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100470079","chemotherapy-supported-by-autologous-hematopoietic-stem-cells-100470079",false,"NCT05401162","Chemotherapy Supported by Autologous Hematopoietic Stem Cells","Conventional Dose Chemotherapy for Ovarian Cancer Supported by Autologous Haematopoietic Stem Cell Transfusion","Inclusion Criteria:\n\n* 18-60 years old;\n* there are chemotherapy indicators for ovarian cancer;\n* ovarian cancer diagnosed by histopathology;\n* recurrent and metastatic ovarian cancer;\n* the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;\n* the expected survival time was more than 3 months;\n* pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative;\n* all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment;\n* the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations;\n* bone marrow function is good,ability to perform stem cell mobilisation and collection.\n\nExclusion Criteria:\n\n* patients with bone marrow disease;\n* central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology;\n* patient has severe cardiac insufficiency;\n* previous history of allogeneic stem cell transplantation or organ transplantation;\n* patients with active bleeding and autoimmune thrombocytopenic purpura;\n* patients with chemotherapy contraindications;\n* positive for human immunodeficiency virus (HIV);\n* acute or chronic active hepatitis B or hepatitis C infection.","FEMALE","18 Years","60 Years",{"count":68,"type":69},40,"ESTIMATED","INTERVENTIONAL",[72],"NA","The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.",[75],"Ovarian Cancer",[75,77,78,79],"Conventional chemotherapy","blood stem cells","autologous blood transfusion","2026-06-24",{"date":82,"type":83},"2026-06-29","ACTUAL",{"date":85,"type":83},"2022-04-15",{"date":87,"type":69},"2029-05",{"name":5,"class":6},1]